Newron’s sarizotan secures FDA rare paediatric status in Rett syndrome

This article was originally published here

Sarizotan was granted the orphan drug designation from the FDA for the treatment of the rare neurodevelopmental disorder. Rett syndrome is known to affect mainly females and currently

The post Newron’s sarizotan secures FDA rare paediatric status in Rett syndrome appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply